OncLive TV

Rohit Kumar, MD, discusses the current and future uses of triplet combinations in metastatic renal cell carcinoma.

Carmelo Carlo-Stella, MD, PhD, discusses the evaluation of subcutaneous and intravenous RG6234 in relapsed/refractory multiple myeloma.

Bartosz Chmielowski, MD, discusses the current treatment landscape of metastatic melanoma.

Carla Falkson, MD, MBChB, MMed, discusses the use of the antibody-drug conjugate sacituzumab govitecan-hziy in hormone receptor–positive, HER2-negative breast cancer.

Stephen V. Liu, MD, discusses the future of MET-targeted agents in non–small cell lung cancer based on the FDA breakthrough designation for telisotuzumab vedotin.

Stephanie A. Berg, DO, discusses the promise of key updates in urothelial cancer, as well as highlights how these updates continue to affect treatment decisions for patients.

John O. Mascarenhas, MD, discusses evolution of JAK inhibitors in the treatment landscape of myelofibrosis.

David Siegel, MD, PhD, discusses the importance of investigating idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

Thomas Herzog, MD, discusses how the recent FDA approval of the novel antibody-drug conjugate mirvetuximab soravtansine-gynx ameliorates unmet need in platinum-resistant, folate receptor alpha–positive gynecological cancers.

Henry S. Park, MD, MPH, discusses key considerations when selecting an optimal treatment approach for patients with stage II and III non–small cell lung cancer.

Petros Grivas, MD, PhD, discusses the investigation of enfortumab vedotin and pembrolizumab in metastatic urothelial carcinoma.

John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses the rationale for evaluating lapatinib (Tykerb) with standard trastuzumab/chemotherapy regimen in patients with HER2-positive breast cancer, as well as contextualizes results from a phase 2 trial.

Andrew Kuykendall, MD, discusses the evaluation of momelotinib in patients with symptomatic and anemic myelofibrosis.

Judy C. Boughey, MD, discusses the significance of results from the phase 2 ACOSOG Z11102 trial evaluating breast conserving therapy in multiple ipsilateral breast cancer. 

Joseph D. Khoury, MD, discusses the importance of differentiating between blastic plasmacytoid dendritic cell neoplasm and acute myeloid leukemia.

Naval Daver, MD, discusses the unmet needs for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm.

Julie Lang, MD, discusses potential applications for the Parsortix® PC1 system in metastatic breast cancer.

Eunice Wang, MD, discusses the utility of minimal residual disease testing in hematologic malignancies and challenges associated with expanding its role in clinical practice for acute myeloid leukemia.

Mitesh J. Borad, MD, discusses the unique mechanism of action of next-generation FGFR inhibitors like KIN-3248 and their potential effect on patient outcomes in cholangiocarcinoma and urothelial cancer.

David Siegel, MD, discusses the significance of updated data from cohort 2C of the phase 2 KarMMa-2 trial in multiple myeloma.

Emma Searle, MD, discusses early findings from cohort E of the phase 1b MajesTEC-2 trial (NCT04722146) evaluating teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) and lenalidomide (Revlimid) in multiple myeloma. 

Roy S. Herbst, MD, PhD, discusses the significance of the FDA approval of adjuvant pembrolizumab in patients with non–small cell lung cancer.

Drew Moghanaki, MD, MPH, discusses questions that still need to be addressed following the phase 3 CheckMate-816 trial of the neoadjuvant combination nivolumab plus chemotherapy in patients with non–small cell lung cancer.

Brian Ramnaraign, MD, discusses the evaluation of atezolizumab plus tivozanib in a phase 1b/2 trial in patients with pancreatic, gallbladder, and bile duct cancers.

Ricardo Costa, MD, MSC, discusses the use of neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab monotherapy, in patients with high-risk, early-stage triple-negative breast cancer.

Michael Maris, MD, discusses key efficacy and safety data from the phase 2 OUTREACH trial in diffuse large B-cell lymphoma.

Mitul Gandhi, MD, discusses key findings from part C of the phase 2 SGN35-027 trial in Hodgkin lymphoma.

Marwan G. Fakih, MD, discusses a comparative analysis of the tumor microenvironment in primary tumors vs metastatic tissue in patients with microsatellite stable metastatic colorectal cancer.

J. Randolph (Randy) Hecht, MD, discusses the investigation of XL092 plus atezolizumab in patients with microsatellite stable/microsatellite instability–low metastatic colorectal cancer.

Howard S. Hochster, MD, discusses the evaluation of trastuzumab and pertuzumab vs cetuximab and irinotecan in HER2-amplified metastatic colorectal cancer.